European Healthcare Investor Association (E.H.I.A.)’s Post

Things are heating up in the radiopharmaceutical space with the recent purchases of RayzeBio by BMS and Point Biopharma Global by Eli Lilly. Exciting times! 🚀 "In a sign of how much the radiopharma race has heated up in recent months, BMS is paying $62.50 per share of the San Diego-based biotech, which equates to an equity value of $4.1 billion. This share price is over triple the $18 that RayzeBio secured for its IPO as recently as September, and is even double the $30.50 that the stock was trading at by market close on Friday". According the to the article, "radiopharmaceuticals have been one of the hottest M&A areas of 2023, with Global Data reporting earlier this month that venture capital deals in the space had grown 550% to $408 million compared to 2017 levels. Until yesterday, Lilly had been the standout new entrant by offering $1.4 billion for Point Biopharma Global, a biotech focused on radioligand therapies with in-house manufacturing capabilities". #radiopharmaceuticals #radioisotopes #biotech #venturecapital #investors #mergersandacquisitions #fightingcancer

Global pharma company backs cancer drug developer A UK drug development company co-founded by Australian Tom McCarthy (picture) has attracted strategic investment from a global pharmaceuticals business in a $38 million capital raising round. The company, which is also backed by Australian venture capital, plans clinical trials for its lead cancer drug candidate in Australia late this year. Read more about this, and much more about venture capital and private equity, at: https://lnkd.in/gE-aPUTb #venturecapital #privateequity

The #IPO market in the #biotech sector had a promising start in the first quarter of 2024, with several companies deciding to go public. Additionally, larger biotech companies have strategically acquired smaller yet significant late-stage companies through M&A. This activity indicates a dynamic landscape in the life sciences industry, where new entrants and established players are actively shaping the market. In a remarkable move, Gilead Sciences acquired CymaBay Therapeutics for $4.43 billion in February, demonstrating its strategic efforts to strengthen its position in the #biopharmaceutical market and transform the treatment landscape for people with primary biliary cholangitis. This acquisition is part of a more significant trend in the industry, as seen with Novartis's acquisition of cancer specialist MorphoSys for $2.77 billion and AstraZeneca's $2.41 billion investment in Fusion Pharmaceuticals. These M&As are a testament to the ongoing trend of consolidation and strategic partnerships within the biotech industry as companies strive to expand their portfolios and capabilities. Other notable M&As include: - Johnson & Johnson acquired Ambrx for approximately $2.0 billion - Sanofi to acquire Inhibrx, Inc. for $1.7 billion - GSK acquired Aiolos Bio for $1 billion - Novo Nordisk to acquire Cardior Pharmaceuticals for $1.1 billion Compass Executives #lifesciences #biotechIPO #biotechdeals #mergersandacquisitions #venturecapital

Upstream Bio's $255M IPO signals a strong entry into the competitive respiratory treatment market. Their lead therapy, aimed at treating severe asthma by targeting the TSLP (thymic stromal lymphopoietin) pathway, is poised to challenge dominant players like Amgen’s Tezspire and Sanofi/Regeneron’s Dupixent. This is a high-stakes arena, with asthma therapeutics expected to reach $30B globally by 2030. The timing of Upstream’s IPO is significant, reflecting a wave of biotech fundraising in 2024, despite tighter market conditions. Companies are increasingly turning to public markets as valuations stabilize post-pandemic, indicating investor confidence in innovative therapies with strong clinical potential. For Upstream Bio, the influx of IPO capital will likely fuel late-stage trials and broaden their R&D efforts, enhancing their competitive edge. As they join other major players in this space, it’ll be crucial for Upstream Bio to differentiate through breakthrough data and strategic partnerships. #Pharmaceuticals #Biotech #IPO #AsthmaTherapies #PharmaInnovation #TSLP #ClinicalTrials #Fundraising #Executiverecruitment #TylerLakeConsulting

Find out more about the biggest private biotech investments like never before in our revamped monthly feature! 💰 So, who exactly bagged the biggest healthcare investments in the first month of 2024? 💼 The answer to that question: Jixing Pharmaceuticals, Cour Pharmaceuticals Development Co., Inc., and OnCusp Therapeutics. 🚀 These three companies came out on top, each raising $100 million or more. 📊 But who else raised big, and how did companies perform by location?🌐 Check out our latest article! 👇️ https://loom.ly/pSRhqDk #biotechinvestments #healthcarefunding #investmentnews #healthcarestartups #biginvestments #globalhealth #biotechfinance #healthcareinnovation #investmenttrends #topbiotech

Seven Biopharma Trends to Watch in 2023 Industry predictions for 2023 based on a survey of 150-plus biopharma leaders were recently offered by PPD, Thermo Fisher Scientific’s clinical research business. The biopharma leaders’ expectations could be summed up in one word: “more.” They predicted more decentralization in clinical trials, more platforms for novel therapeutics, more digitalization, more real-world data and evidence, more outsourcing, and more diversity in patient populations. Some of these predictions are among the seven biopharma-related trends that GEN has uncovered in its interviews with experts and other industry stakeholders, and in its reviews of reports and public statements. These trends are detailed in this article. https://ow.ly/fvyO50Qmo5t

#News: There’s been no festive respite for Bristol Myers Squibb ’s M&A team as the #BigPharma follows up its acquisition of Karuna Therapeutics with the announcement straight after Christmas that it's also buying #radiopharmaceuticals-focused #RayzeBio for cash. In a sign of how much the radiopharma race has heated up in recent months, BMS is paying $62.50 per share of the San Diego-based biotech, which equates to an equity value of $4.1 billion. This share price is over triple the $18 that RayzeBio secured for its IPO as recently as September, and is even double the $30.50 that the stock was trading at by market close on Friday. Read more Fierce Biotech 👇🏽 https://lnkd.in/e7PkTRPB

Biotech Funding Update July 15th-19th ‘24 Significant funding events, many to advance clinical stage assets.. Get this weekly • https://lnkd.in/gDGtEEyy – 𝐏𝐫𝐢𝐯𝐚𝐭𝐞 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – Cardurion Pharmaceuticals 💸  Raised $260M in Series B financing led by Ascenta Capital to support late-stage trials of lead drug candidates. Scorpion Therapeutics 💸  Announced $150M Series C financing co-led by Frazier Life Sciences and Lightspeed Venture Partners to advance precision oncology assets. CatalYm GmbH 💸  Announced $150M Series D financing to support Ph 2b development of Visugromab Magenta Medical Ltd. 💸  Closed $105M financing led by several healthcare investors to advance the company's U.S. clinical programs in multiple MCS indications and to secure the first FDA approval for the Elevate™ System in patients undergoing HR-PCI. Asceneuron SA 💸 Secured $100M in Series C financing led by Novo Holdings to advance Ph2 development of ASN51 for treating Alzheimer's disease. – 𝐏𝐨𝐬𝐭-𝐈𝐏𝐎/𝐏𝐮𝐛𝐥𝐢𝐜 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 – Artiva Biotherapeutics 🏦  Raised $167M in an IPO at $12/share. NGM Biopharmaceuticals 🏦  Announced $122M Series A led by TCG funding to initiate PSC trial and fund Ph2 trial in hyperemesis gravidarum. OPKO Health, Inc. 🏦  Announced a $100M share repurchase program. LENZ Therapeutics 🏦  Entered a $30M stock purchase agreement with Ridgeback Capital Investments. MediWound 🏦  Announced a $25M private placement offering. At BiopharmIQ by Amp we maintain biopharma data to help with your sales/BD activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma

The biotech sector is navigating through a transformative phase with remarkable agility. The last few years have indeed been a test for many industries, and biotech was no exception. Amidst a general downturn, it's inspiring to see titans of the biotech industry not just surviving but thriving by capitalising on their flagship products to spearhead new, groundbreaking projects. Companies like Bristol Myers Squibb, Regeneron Pharmaceuticals, and Pfizer, among others, have demonstrated adaptability and foresight, positioning themselves as pivotal players in the sector's anticipated recovery and growth trajectory. What's particularly noteworthy is the strategic pivots these companies have made in response to the evolving market dynamics. For instance, Bristol Myers Squibb's acquisitions aimed at bolstering its oncology portfolio, and Pfizer's diversification beyond its COVID-19 vaccine, underline a broader trend of innovation and strategic expansion. Such adaptability is crucial in an industry where the stakes involve not just financial gains but the advancement of human health and well-being. Looking ahead, the surge in merger and acquisition activities within this elite group of biotech giants is not merely a reaction to market challenges but a proactive strategy to leverage collective strengths for greater innovation and market penetration. As the industry stands on the brink of recovery, these companies are shaping the future of biotech. #AspireLifeSciences #biotech #pfizer #biotechnology https://lnkd.in/dWH3i6YS